EUVIMEDEUVIMED entdecken
Open Access

Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data

Wenjun Fan iD, Chuyue Wu iD, Nathan D Wong iD

Circulation: Genomic and Precision Medicine · 2025

DOI: 10.1161/circgen.124.004631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025. Verfasst von Wenjun Fan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mary and Steve Wen Cardiovascular Division, Department of Medicine (W.F., N.D.W.), University of California, Irvine. Hauptthemen laut MEDLINE: Lipoprotein(a), Atherosclerosis, Primary Prevention, Cardiovascular Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lipoprotein(a) [Lp(a)] is a predictor of atherosclerotic cardiovascular disease (ASCVD); however, there are few algorithms incorporating Lp(a), especially from real-world settings. We developed an electronic health record (EHR)-based risk prediction algorithm including Lp(a). METHODS: Utilizing a large EHR database, we categorized Lp(a) cut points at 25, 50, and 75 mg/dL and constructed 10-year ASCVD risk prediction models incorporating Lp(a), with external validation in a pooled cohort of 4 US prospective studies. Net reclassification improvement was determined among borderline-intermediate risk patients. RESULTS: We included 5902 patients aged ≥18 years (mean age 48.7±16.7 years, 51.2% women, and 7.7% Black). Our EHR model included Lp(a), age, sex, Black race/ethnicity, systolic blood pressure, total and high-density lipoprotein cholesterol, diabetes, smoking, and hypertension medication. Over a mean follow-up of 6.8 years, ASCVD event rates (per 1000 person-years) ranged from 8.7 to 16.7 across Lp(a) groups. A 25 mg/dL increment in Lp(a) was associated with an adjusted hazard ratio of 1.23 (95% CI, 1.10–1.37) for composite ASCVD. Those with Lp(a) ≥75 mg/dL had an 88% higher risk of ASCVD (hazard ratio, 1.88 [95% CI, 1.30–2.70]) and more than double the risk of incident stroke (hazard ratio, 2.55 [95% CI, 1.54–4.23]). C-statistics for our EHR and EHR+Lp(a) models in our EHR training data set were 0.7475 and 0.7556, respectively, with external validation in our pooled cohort (n=21 864) of 0.7350 and 0.7368, respectively. Among those at borderline/intermediate risk, the net reclassification improvement was 21.3%. CONCLUSIONS: We show the feasibility of developing an improved ASCVD risk prediction model incorporating Lp(a) based on a real-world adult clinic population. The inclusion of Lp(a) in ASCVD prediction models can reclassify risk in patients who may benefit from more intensified ASCVD prevention efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)AtherosclerosisPrimary PreventionCardiovascular DiseasesHumansFemaleMiddle AgedMaleAdultElectronic Health RecordsAgedRisk AssessmentRisk FactorsAlgorithmsProspective Studies

Stichwörter der Autor:innen

cardiovascular diseaseelectronic health recordslipoprotein(a)risk assessment

Substanzen

Lipoprotein(a)

Autor:innen und Institutionen

  • Mary and Steve Wen Cardiovascular Division, Department of Medicine (W.F., N.D.W.), University of California, Irvine.
  • Department of Epidemiology and Biostatistics (W.F., N.D.W.), University of California, Irvine.
  • Department of Epidemiology (C.W., N.D.W.), University of California, Los Angeles.

ORCID-Profile: Wenjun Fan, Chuyue Wu, Nathan D Wong

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NCRR NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Fan, W., Wu, C., & Wong, N. D. (2025). Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.124.004631

Vancouver

Fan W, Wu C, Wong ND. Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data. Circulation: Genomic and Precision Medicine. 2025. doi:10.1161/circgen.124.004631

BibTeX
@article{Fan2025,
  author = {Fan, Wenjun and Wu, Chuyue and Wong, Nathan D},
  title = {Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2025},
  doi = {10.1161/circgen.124.004631}
}
Kostenlos starten →